Log in

Start Your Membership Now

About 30% of artificial intelligence (AI) pilots intended for health care applications reach the production phase of the software development lifecycle, based on a recent survey conducted by Bessemer Venture Partners, Bain & Company, and Amazon Web Services. The survey respondents said that security, data readiness, integration costs, and limited in-house expertise affected whether a pilot reached production. However, 80% of surveyed leaders across the more than 400 included health care payers, provider organizations, and pharmaceutical companies said they believe that generative AI (GenAI) will transform clinical decision-making in the near future.

GenAI is an AI platform that . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Tagged As: